e-learning
resources
Stockholm 2007
Sunday 16.09.2007
Granulomatous lung diseases including sarcoidosis
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
The use of symbicort in the treatment of patients with I and II stages of pulmonary sarcoidosis
N. Refitskaya (Saint-Petersburg, Russian Federation)
Source:
Annual Congress 2007 - Granulomatous lung diseases including sarcoidosis
Session:
Granulomatous lung diseases including sarcoidosis
Session type:
Thematic Poster Session
Number:
643
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
N. Refitskaya (Saint-Petersburg, Russian Federation). The use of symbicort in the treatment of patients with I and II stages of pulmonary sarcoidosis. Eur Respir J 2007; 30: Suppl. 51, 643
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Emerging classes of drugs for the treatment of obstructive lung disease
Pulmonary sarcoidosis
Related content which might interest you:
The use fluimucil (N-acetylcysteine) in the treatment in patients with III and IY stages of pulmonary sarcoidosis
Source: Eur Respir J 2004; 24: Suppl. 48, 713s
Year: 2004
The use of plasmapheresis in the treatment of patients with IY stage of pulmonary sarcoidosis
Source: Eur Respir J 2002; 20: Suppl. 38, 434s
Year: 2002
The experience of use plasmaferesis in complex treatment in patients with pulmonary sarcoidosis (PS)
Source: Annual Congress 2008 - Clinical aspects in the management of sarcoidosis
Year: 2008
Respiratory function in stage II pulmonary sarcoidosis patients
Source: Eur Respir J 2001; 18: Suppl. 33, 385s
Year: 2001
The radiographic stage and pulmonary function of patients with sarcoidosis
Source: Annual Congress 2007 - Granulomatous lung diseases including sarcoidosis
Year: 2007
Isophonum usage in treatment of patients with pulmonary tuberculosis and accompanying pathology and elderly patients
Source: Eur Respir J 2002; 20: Suppl. 38, 547s
Year: 2002
Evaluating the effects of pulmonary rehabilitation in patients with COPD in early and late disease stages.
Source: Annual Congress 2008 - Impact of rehabilitation programmes in COPD and non-COPD patients
Year: 2008
Evolution of systemic response in patients with pulmonary sarcoidosis of different course of the disease during anti-inflammatory treatment
Source: Annual Congress 2009 - Sarcoidosis in review
Year: 2009
The role of determining the levels of collagen type IV in the management of patients with severe chronic obstructive pulmonary disease – Focus on roflumilast
Source: International Congress 2015 – New data on established treatments for asthma and COPD
Year: 2015
The course of COVID-19 in pulmonary sarcoidosis patients, receiving methotrexate
Source: Virtual Congress 2021 – Moving forward in various aspects of sarcoidosis
Year: 2021
Contemporary surgical issues in NSCLC treatment
Source: Annual Congress 2007 - PG7 - Thoracic oncology: nonsmall cell lung cancer
Year: 2007
The pharmacotherapy options for the intensive treatment phase in patients with primarily diagnosed pulmonary tuberculosis
Source: Annual Congress 2012 - Tuberculosis: clinical findings II
Year: 2012
Efficacy of different preoperational treatment in patients with destructive pulmonary TB
Source: Eur Respir J 2005; 26: Suppl. 49, 688s
Year: 2005
Phase 2 clinical trial of PBI-4050 in patients with idiopathic pulmonary fibrosis
Source: Eur Respir J, 53 (3) 1800663; 10.1183/13993003.00663-2018
Year: 2019
Long-term treatment with clarithromycin of stage II COPD patients with frequent exacerbations
Source: Annual Congress 2008 - Management of COPD
Year: 2008
Prevalence, features of the course and treatment efficacy airway obstruction in patients with newly diagnosed pulmonary tuberculosis
Source: Annual Congress 2012 - Tuberculosis: clinical findings I
Year: 2012
Stage IV sarcoidosis: comparison of survival with the general population and causes of death
Source: Eur Respir J 2011; 38: 1368-1373
Year: 2011
Effects of pulmonary rehabilitation on peripheral muscle fibre characteristics in COPD patients with gold stages II to IV
Source: Annual Congress 2009 - Emerging physiology behind pulmonary rehabilitation
Year: 2009
Effects of pulmonary rehabilitation on systemic inflammation in patients with advanced COPD
Source: Eur Respir J 2005; 26: Suppl. 49, 721s
Year: 2005
The effectiveness of pulmonary rehabilitation in patients diagnosed with interstitial pulmonary fibrosis
Source: Virtual Congress 2020 – The multiple facets of pulmonary rehabilitation and chronic respiratory care
Year: 2020
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept